Summary
An open label, non-controlled trial of six-month duration was designed to determine the safety and efficacy of auranofin in the treatment of 13 children with polyarticular JRA. Adverse reactions were observed in 5 of the 13 patients (38%) but only in one was it serious enough to discontinue treatment. None of the patients developed diarrhea or hematologic abnormalities. Therapeutic response was evaluated in the 11 patients who completed the six-month treatment. According to the final overall assessment 9 of the 11 children had improved, one remained unchanged and one worsened. After four months of treatment serum gold levels in 11 patients ranged between 28 and 59μg/dl, with a mean value of 34μg/dl. There was no correlation between serum gold levels and the frequency and severity of side effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hanson, V. Dosage of gold salts in treatment of juvenile rheumatoid arthritis. Arthritis Rheum, 1977, 20, 548. (Suppl).
Levinson, J.E., Balz, G.P., Bondi, S. Gold therapy. Arthritis Rheum, 1977, 20, 531–535. (Suppl).
Brewer, E.J., Giannini, E.H., Barkley, E. Gold therapy in the management of juvenile rheumatoid arthritis. Arthritis Rheum, 1980, 23, 404–411.
Orozco-Alcalá, J., Baum, J. Treatment of juvenile rheumatoid arthritis. A world survey. J. Rheumatol, 1974, 1, 187–189.
Finkelstein, A.E., Walz, D.T., Batista, V., et al. Auranofin. New oral gold compound for treatment of rheumatoid arthritis. Ann Rheum Dis, 1976, 35, 251–257.
Weisman, M.H., Hannifin, D.M. Management of rheumatoid arthritis with oral gold. Arthritis Rheum, 1979, 22, 922–925.
Bandilla, K., Gross, D., Gross, W., et al. Oral gold therapy with auranofin (SK&F 39162). A multicenter open study in patients with rheumatoid arthitis. J Rheumatol, 1982, 9, 154–159. (Suppl 8).
Katz, W.A., Alexander, S., Bland, J.H., et al: The efficacy and safety of auranofin compared to plaebo in rheumatoid arthritis. J Rheumatol, 1982, 9, 173–178. (Suppl 8).
Schattenkirchner, M., Kaik, B., Muller-Fassbender, H., et al.: Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis. A double blind, comparative, multicenter study. J Rheumatol, 1982, 9, 184–189. (Suppl 8).
Giannini, E.H., Brewer, E.J., Person, D.A. Auranofin in the treatment of juvenile rheumatoid arthritis. J Pediatr, 1983, 102, 138–141.
JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee. American Rheumatism Association. Current proposed revision of JRA Criteria. Arthritis Rheum, 1977, 20, 195–199, (Suppl).
Menard, H.A., Beaudet, F., Davis, P., et al. Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicenter prospective trial comparing sodium aurothiomalate and auranofin. J Rheumatol, 1982, 9, 179–183, (Suppl 8).
Homma, M., Abe, T., Akizuki, M., et al. Interim results of a multicenter open study with auranofin in Japan, J Rheumatol, 1982, 9, 160–168, (Suppl 8).
Plaza, J.J., Herrero, G., Barat, A., et al. Membranous glomerulonephritis as a complication of oral gold therapy. Ann Intern Med, 1982, 97, 563–564.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garcia-Morteo, O., Suarez-Almazor, M.E., Maldonado-Cocco, J.A. et al. Auranofin in juvenile rheumatoid arthritis. An open label, non-controlled study. Clin Rheumatol 3, 223–227 (1984). https://doi.org/10.1007/BF02030759
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02030759